Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome

A Multicentre, Open Label, Non-interventional Study to Evaluate on Long-term Safety and Efficacy of Norditropin® Formulation in Child Patients With GHD or Turner Short Stature Without Closure of Epiphyseal Discs.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01604161

Acronym

NordiPAD

Enrollment

2016

Registered

2012-05-23

Start date

2005-05-31

Completion date

2015-06-30

Last updated

2015-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Disorder, Growth Hormone Deficiency in Children, Growth Hormone Disorder, Turner Syndrome

Brief summary

This study is conducted in Japan. The aim of this study is to collect information about the efficacy and safety of Norditropin® (somatropin) in the long-term treatment of short stature with GHD (Growth Hormone Deficiency) where epiphysial discs are not closed and short stature with Turner Syndrome where epiphysial discs are not closed.

Interventions

DRUGsomatropin

Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Growth hormone deficiency or short stature due to Turner Syndrome where the epiphyseal discs are not closed

Exclusion criteria

* Diabetic * Patients with malignant tumors * Women who are either pregnant or likely to be pregnant * Known or suspected allergy to study product(s) or related products

Design outcomes

Primary

Measure	Time frame
Change from baseline in height	Week 0, Month 36, final height is reached
Incidence of adverse reactions (ADRs)	36 months, accumulation of study period

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026